Yazar "Jokubaitis, V." için listeleme

Toplam kayıt 14, listelenen: 1-14

Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider, J.; Jokubaitis, V.; Spelman, T.; Izquierdo, G.; Lugaresi, A.; Havrdova, E.; Ramo-Tello, C. (Sage Publications Ltd, 2016)

…
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Barnett, M. (Sage Publications Ltd, 2017)

…
Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; Wiendl, H.; Lechner-Scott, J. (Sage Publications Ltd, 2015)

…
Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Kalincik, T.; Horakova, D.; Spelman, T.; Jokubaitis, V.; Trojano, M.; Lugaresi, A.; Bergamaschi, R. (Sage Publications Ltd, 2014)

…
Contribution of inflammation to disability accrual in primary progressive multiple sclerosis

Hughes, J.; Jokubaitis, V.; Spelman, T.; Lugaresi, A.; Hupperts, R.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2017)

…
Defining secondary progressive multiple sclerosis

Lorscheider, J.; Buzzard, K.; Jokubaitis, V.; Spelman, T.; Havrdova, E.; Horakova, D.; Van Pesch, V. (Sage Publications Ltd, 2015)

…
Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Trojano, M.; Pucci, E. (Sage Publications Ltd, 2017)

…
Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)

…
Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Butzkueven, H.; Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; La Spitaleri, D. (Sage Publications Ltd, 2016)

…
Evaluation of common criteria of progression of disability in a large observational cohort

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Terzi, M. (Sage Publications Ltd, 2014)

…
Individual response to disease modifying therapies: a global observational cohort study

Kalincik, T.; Sobisek, L.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Granella, F. (Sage Publications Ltd, 2016)

…
The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Brown, J. W. L.; Lugaresi, A.; Horakova, D.; Havrdova, E.; Jokubaitis, V.; Lechner-Scott, J.; Hutchinson, M. (Sage Publications Ltd, 2017)

…
Risk of secondary progressive multiple sclerosis: a longitudinal study [Meeting Abstract]

Fambiatos, A.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Granella, F. (Sage Publications Ltd, 2017)

…
Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Merkel, B.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Spitaleri, D. (Sage Publications Ltd, 2017)

…